[Skip to Content]
[Skip to Content Landing]
Less Is More
June 11, 2012

The Dilemma of Prostate-Specific Antigen Testing

Author Affiliations

Author Affiliations: Department of Urology, University of Texas Health Science Center at San Antonio.

Arch Intern Med. 2012;172(11):835-836. doi:10.1001/archinternmed.2012.1226

For a man with prostate cancer, treatment decision making is daunting. If the tumor is high grade, decision making may be straightforward because disease-specific mortality is high despite the toxicity of combined therapies that are proved to reduce mortality (eg, radiation and hormonal therapy).1 For a man with an aggressive tumor, while decision making requires considerable thought, information, and support by the treating physician, the possibility of adverse effects often dims when there is an opportunity to improve survival.